Annexon (NASDAQ: ANNX) maps 2026 neuroinflammatory immunotherapy milestones

Rhea-AI Filing Summary

Annexon, Inc. reported that it issued a press release outlining its 2026 strategic priorities and key milestones for its lead programs. The press release, titled “Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026,” focuses on advancing its next-generation targeted immunotherapy platform for neuroinflammatory diseases and highlights multiple planned registrational milestones in 2026. The full details are provided in the press release attached as Exhibit 99.1 to this report.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001528115 0001528115 2026-01-12 2026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

ANNEXON, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39402		27-5414423
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1400 Sierra Point Parkway, Bldg C, Suite 200 Brisbane, California		94005
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (650) 822-5500

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ANNX		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On January 12, 2026, Annexon, Inc. issued a press release titled “Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026” announcing its 2026 strategic priorities and key milestones for its lead programs. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated January 12, 2026, titled “Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026”.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Annexon, Inc.
Date: January 12, 2026				By:		/s/ Jennifer Lew
						Jennifer Lew
						Executive Vice President and Chief Financial Officer

FAQ

What did Annexon, Inc. (ANNX) disclose in this 8-K filing?

Annexon, Inc. disclosed that it issued a press release describing its 2026 strategic priorities and key milestones for its lead programs, particularly for its targeted immunotherapy platform for neuroinflammatory diseases.

What is the focus of Annexon, Inc.’s 2026 strategic priorities?

The 2026 strategic priorities focus on accelerating Annexon’s next generation targeted immunotherapy platform aimed at the treatment of neuroinflammatory diseases.

What key milestones did Annexon, Inc. reference for 2026?

The company referenced multiple registrational milestones in 2026 related to its lead programs within its targeted immunotherapy platform for neuroinflammatory diseases, as described in the attached press release.

Which exhibit contains the Annexon, Inc. press release in the 8-K?

The press release titled “Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026” is included as Exhibit 99.1.

Does this Annexon, Inc. 8-K include detailed financial results?

No detailed financial results are described in this content; the filing centers on strategic priorities and program milestones summarized in the attached press release.

Who signed the Annexon, Inc. 8-K report?

The report was signed on behalf of Annexon, Inc. by Jennifer Lew, who serves as Executive Vice President and Chief Financial Officer.